Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 13:17:171-187.
doi: 10.2147/CEOR.S495401. eCollection 2025.

Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy

Alessandra Di Costanzo  1 , Luca Loreto  1 , Chiara Vassallo  1 , Francesca Fiorentino  1
Affiliations

Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy

Alessandra Di Costanzo et al. Clinicoecon Outcomes Res. .

Abstract

Purpose: Intravenous (IV) decitabine is a therapeutic option for patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy. Recently, the oral formulation of decitabine-cedazuridine demonstrated comparable efficacy and safety to IV decitabine, and pharmacokinetic equivalence. This study estimates the direct non-drug healthcare costs of IV decitabine administration in Italy, including central venous catheter (CVC) and infection management, and assesses the economic impact of oral decitabine introduction.

Methods: A micro-costing analysis from the Italian National Health Service (NHS) perspective was developed in four steps: 1) identification of the phases of IV and oral decitabine administration process, including CVC and infection management; 2) estimation of resource consumption, frequencies and proportion of patients for each phase; 3) collection of unit costs; 4) development of a cost analysis model. Inputs were retrieved from literature, public sources, IQVIA proprietary databases and a panel composed of clinicians, nurses and hospital pharmacists working in oncology departments. Two scenarios were explored: the first applying the economic impact to the population of interest over three years, the second including the cost of blood transfusions.

Results: The analysis estimated a total non-drug administration cost per patient of € 3574.6 and € 781.4 for a treatment course with IV and oral decitabine, respectively, leading to a cost impact of oral drug introduction of - € 2793.2 (-78.1%). The first scenario estimated a total saving for the Italian NHS of € 1.09 million over three years, the second scenario estimated a potential additional impact of - € 3418.6/patient due to transfusions.

Conclusion: The administration of oral versus IV decitabine is expected to generate cost savings for the Italian NHS in terms of drug administration, CVC and infection management, in patients with AML ineligible for induction chemotherapy.

Keywords: administration route; cost analysis; economic evaluation; infections; intravenous therapy; oral therapy.

PubMed Disclaimer

Conflict of interest statement

At the time of the start of the project and the drafting of the manuscript, ADC, LL, CV and FF were employees of IQVIA Solutions Italy s.r.l., a company that receives professional service commissions from a large number of sponsors for a variety of activities in the biopharmaceutical sector. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Cost per patient per whole treatment duration by treatment type and cost component.
Figure 2
Figure 2
Tornado diagram presenting sensitivity analysis results.
Figure 3
Figure 3
Cost impact of oral drug introduction by year.
Figure 4
Figure 4
Cost impact per patient including blood transfusion cost.
See this image and copyright information in PMC

References

    1. Damiani D, Tiribelli M. Molecular landscape in adult acute myeloid leukemia: where we are where we going? J Lab Precis Med. 2019;4:17. doi:10.21037/jlpm.2018.09.08 - DOI
    1. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87. doi:10.1016/j.blre.2019.04.005 - DOI - PubMed
    1. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441–e441. doi:10.1038/bcj.2016.50 - DOI - PMC - PubMed
    1. AIRTUM. I numeri del cancro in Italia, 2023. (The numbers of cancer in Italy, 2023) Available from: https://www.registri-tumori.it/cms/pubblicazioni/i-numeri-del-cancro-ita.... Accessed May, 2024.
    1. Calabria S, Ronconi G, Dondi L, et al. Acute myeloid leukemia: incidence, transplantation and survival through Italian administrative healthcare data. Tumori. 2023;109(5):496–503. doi:10.1177/03008916231153698 - DOI - PubMed